Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study

Table 2

Vascular events after discontinuation of vitamin K antagonist treatment.

Total follow-up off-treatment	211.8 patient-years
Follow-up time, median (IQR)	1.6 (0.5–3.3) years
Cumulative incidence of vascular events, (%)	7/90 (7.8%)
Incidence rate of vascular events (95% CI)	3.3 (1.6–6.9) per 100 patient-years
Time elapsed from discontinuation of VKA treatment to the first vascular event, median (IQR)	0.5 (0.3–0.9) years
Type of vascular events
Venous thrombotic events,	6
SVT recurrence,
Lower limb proximal or distal DVT,	2
Renal vein thrombosis,	1
Arterial thrombotic events,	1
Acute coronary syndrome,	1

Two recurrent SVT were diagnosed incidentally in cirrhotic patients undergoing abdominal imaging as follow-up of their liver disease (portal vein and portomesenteric veins thrombosis); a suprahepatic vein thrombosis was diagnosed in a patient with polycythemia vera presenting with abdominal pain and ascites.
DVT = deep vein thrombosis, IQR = interquartile range, PE = pulmonary embolism, SVT = splanchnic vein thrombosis, and VKA = vitamin K antagonist.